Correct Answer: D. DC cardioversion
The clinical presentation—hypotension (90/40 mm Hg), feeble pulse, and a tachyarrhythmia (implied by the rhythm strip context)—indicates hemodynamic instability. In an unstable patient with a symptomatic arrhythmia, the immediate management priority is electrical therapy, not pharmacological conversion. DC cardioversion is the gold standard for any hemodynamically unstable arrhythmia (whether SVT, VT, or atrial fibrillation with RVR), as it rapidly restores sinus rhythm and perfusion. The patient's low blood pressure and weak pulse mean there is insufficient time for drugs to take effect; immediate electrical therapy is life-saving. According to AHA/BLS guidelines and Indian cardiology practice (as per CSCI recommendations), hemodynamically unstable patients require synchronized DC cardioversion under sedation (if conscious) or without delay. Pharmacological agents like adenosine, diltiazem, or ibutilide are reserved for stable patients with preserved hemodynamics and are contraindicated in shock states because they may worsen hypotension or cause asystole.
Why the other options are wrong
A. IV adenosine — Adenosine is a first-line agent for stable SVT but is absolutely contraindicated in hemodynamic instability. It causes transient AV block and can precipitate asystole, severe bradycardia, or hypotension—catastrophic in a patient already in shock (BP 90/40). Adenosine requires intact perfusion to work; this patient needs immediate electrical therapy. B. IV diltiazem — Diltiazem is a rate-control agent for stable atrial fibrillation or SVT but is a negative inotrope and vasodilator. In a hypotensive patient (90/40 mm Hg), it will worsen shock, reduce cardiac output further, and delay restoration of perfusion. Pharmacological rate control is inappropriate when the patient is hemodynamically unstable. C. Ibutilide — Ibutilide is a Class III antiarrhythmic used for pharmacological cardioversion of atrial fibrillation or flutter in stable patients. It prolongs QT interval and carries a risk of torsades de pointes. In hemodynamic collapse, it delays definitive therapy and offers no immediate hemodynamic benefit; DC cardioversion is faster and safer.
High-Yield Facts
- Hemodynamic instability (SBP <90 mm Hg, altered mental status, shock) mandates immediate synchronized DC cardioversion regardless of arrhythmia type.
- Adenosine is contraindicated in hypotension and shock; it causes transient asystole and worsens perfusion.
- Diltiazem and other negative inotropes are forbidden in cardiogenic shock; they reduce cardiac output and deepen hypotension.
- Synchronized DC cardioversion is the definitive, time-saving therapy for unstable SVT, VT, and rapid atrial fibrillation.
- Pharmacological conversion (adenosine, ibutilide, diltiazem) is reserved for hemodynamically stable patients with preserved blood pressure and perfusion.
Mnemonics
UNSTABLE = SHOCK → SHOCK THERAPY (DC cardioversion) If patient is UNSTABLE (hypotensive, altered, feeble pulse, shock), give SHOCK (electrical therapy). If STABLE, give drugs (adenosine, diltiazem, etc.). Use this at the bedside: check BP and perfusion first, then decide electrical vs. pharmacological. ACLS Rule: Hemodynamic Instability → Cardioversion First Adenine drugs (adenosine) are for Acute stable SVT. Cardioversion is for Critical (unstable) patients. This is the ACLS hierarchy taught in Indian ICU protocols.
NBE Trap
NBE pairs "arrhythmia + drug name" to lure students into choosing a pharmacological agent without assessing hemodynamic stability first. The trap is forgetting that stability status trumps arrhythmia type—an unstable patient with any rhythm needs electricity, not chemistry.
Clinical Pearl
In Indian ICUs, the "feeble pulse + low BP" triad is the red flag for immediate cardioversion. Many residents mistakenly reach for adenosine or diltiazem in panic; the correct reflex is to call for the defibrillator and sedate the patient (if conscious) before shocking. This saves lives in acute coronary syndrome with malignant arrhythmias—common in Indian diabetic and hypertensive populations.
_Reference: Harrison Ch. 226 (Arrhythmias); AHA/BLS Guidelines 2020; CSCI Consensus on Arrhythmia Management_